{"title":"Pain Intensity and Hazardous Cannabis Use: The Moderating Role of Pain-related Anxiety.","authors":"Victoria E Carlin, Lisa R LaRowe, Joseph W Ditre","doi":"10.1080/02791072.2025.2511756","DOIUrl":"https://doi.org/10.1080/02791072.2025.2511756","url":null,"abstract":"<p><p>Although cannabis has gained attention as a potential treatment for chronic pain, hazardous cannabis use (i.e. patterns of use that have harmful consequences) has been linked to negative health outcomes. Pain intensity is associated with greater cannabis use, and individuals with greater pain-related anxiety may be more likely to respond to pain with substance use. However, no prior work has examined the role of pain-related anxiety in hazardous cannabis use among individuals with chronic pain. The current analyses tested whether pain-related anxiety moderates associations between pain intensity and hazardous cannabis use. Participants included 80 cannabis users with chronic pain (63% male; 67% White; <i>M</i><sub><i>age</i></sub> = 33.6). Results indicated a positive interaction between pain intensity and pain-related anxiety on hazardous cannabis use (<i>p</i> < .05), such that pain intensity was positively associated with hazardous cannabis use among individuals with moderate and high pain-related anxiety, but not those with low pain-related anxiety, suggesting that pain-related anxiety may function as a transdiagnostic vulnerability factor for greater co-occurring pain and hazardous cannabis use. Future work should examine longitudinal associations between pain, pain-related anxiety, and hazardous cannabis use. There may be clinical utility in addressing pain-related anxiety among cannabis users with chronic pain.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study.","authors":"Brandon Biba, Brian A O'Shea","doi":"10.1080/02791072.2025.2511750","DOIUrl":"https://doi.org/10.1080/02791072.2025.2511750","url":null,"abstract":"<p><p>New methods that capture the public's perception of controversial topics may be valuable. This study investigates public sentiments toward psychedelics and other substances through analyzes of Reddit discussions, using Google's cloud-based Natural Language Processing (NLP) infrastructure. Our findings indicate that illicit substances such as heroin and methamphetamine are associated with highly negative general sentiments, whereas psychedelics like Psilocybin, LSD, and Ayahuasca generally evoke neutral to slightly positive sentiments. This study underscores the effectiveness and cost efficiency of NLP and machine learning models in understanding the public's perception of sensitive topics. The findings indicate that online public sentiment toward psychedelics may be growing in acceptance of their therapeutic potential. However, limitations include potential selection bias from the Reddit sample and challenges in accurately interpreting nuanced language using NLP. Future research should aim to diversify data sources and enhance NLP models to capture the full spectrum of public sentiment toward psychedelics. Our findings support the importance of ongoing research and public education to inform policy decisions and therapeutic applications of psychedelics.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Araam Abboud, Clay Schiebrel, Ramzi W Nahhas, Sam Durkin, Kyle Hua, Hannah Redding, Danielle Gainer
{"title":"Patients' Attitudes Toward Hallucinogenic and Non-Hallucinogenic Psilocybin for Mental Health Treatment.","authors":"Araam Abboud, Clay Schiebrel, Ramzi W Nahhas, Sam Durkin, Kyle Hua, Hannah Redding, Danielle Gainer","doi":"10.1080/02791072.2025.2511752","DOIUrl":"https://doi.org/10.1080/02791072.2025.2511752","url":null,"abstract":"<p><p>This study examined patient perspectives on psilocybin therapy, specifically their acceptance and views on the therapeutic benefits of both hallucinogenic and non-hallucinogenic forms. A cross-sectional survey was conducted among psychiatric patients aged 18-65 at a community mental health center, assessing their attitudes, knowledge, and acceptance of psilocybin therapy. In total, 62.4% of the participants expressed openness to hallucinogenic psilocybin (<i>p</i> = .009), while 60.4% were open to non-hallucinogenic forms (<i>p</i> = .023). Patients with major depressive disorder preferred hallucinogenic therapy more (<i>p</i> = .010), while those with borderline personality disorder (BPD) (<i>p</i> = .030) and post-traumatic stress disorder (PTSD) (<i>p</i> = .035) favored non-hallucinogenic options, possibly due to concerns about the intensity of hallucinogenic experiences. Individuals with substance use disorder (SUD) demonstrated a greater acceptance of both hallucinogenic (<i>p</i> = .007) and non-hallucinogenic forms (<i>p</i> = .046) than individuals without SUD. These findings suggest that societal stigma is not a significant barrier to psilocybin therapy and that non-hallucinogenic forms may provide a more accessible option for certain patient groups. Understanding patient perspectives on psilocybin therapy, including vulnerability to adverse hallucinogenic experiences, can inform personalized and effective treatments for resistant conditions.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B Romeo, E Kervadec, B Fauvel, L Strika-Bruneau, A Amirouche, V Verroust, P Piolino, A Benyamina
{"title":"Exploring Factors Affecting Psychological Flexibility After Psychedelic Experiences.","authors":"B Romeo, E Kervadec, B Fauvel, L Strika-Bruneau, A Amirouche, V Verroust, P Piolino, A Benyamina","doi":"10.1080/02791072.2025.2495937","DOIUrl":"https://doi.org/10.1080/02791072.2025.2495937","url":null,"abstract":"<p><p>Neurobiological effects and psychological models propose that psychedelics may promote psychological flexibility, suggesting a transdiagnostic effect by disrupting maladaptive patterns. The objective of this study was therefore to investigate the determinants of psychological flexibility change following a psychedelic use. This retrospective online survey included French individuals who had undergone a significant psychedelic experience. Participants were assessed for mystical experience intensity with the MEQ-30, and psychological flexibility via the AAQ-II, at three retrospective time points. Data analysis comprised descriptive statistics, correlation analysis, ANCOVA to evaluate the impact of psychedelic use variables on psychological flexibility, and linear regression to identify predictors of psychological flexibility changes. Data showed a positive correlation between mystical experience intensity and improvements in psychological flexibility, especially 1-month post-experience (<i>p</i> < .01), and during the 6 months before the survey (<i>p</i> < .01). Key predictors of changes in psychological flexibility included baseline AAQ-II scores, MEQ total scores and frequent psychedelic use, underlining the interaction between personal and experiential factors in determining therapeutic outcomes. In conclusion, this study highlights how the intensity of mystical experience and baseline psychological flexibility may be the key factors influencing changes in psychological flexibility post-psychedelic use, suggesting a potential therapeutic value.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicolas G Glynos, Mallet R Reid, Jacob S Aday, Daniel J Kruger, Kevin F Boehnke, Stephanie Lake, Philippe Lucas
{"title":"Racial Differences in Naturalistic Psychedelic Use - Motivations for Use, Communication with Health Care Providers, and Outcomes.","authors":"Nicolas G Glynos, Mallet R Reid, Jacob S Aday, Daniel J Kruger, Kevin F Boehnke, Stephanie Lake, Philippe Lucas","doi":"10.1080/02791072.2025.2491381","DOIUrl":"https://doi.org/10.1080/02791072.2025.2491381","url":null,"abstract":"<p><p>People of Color have been under-included in psychedelic-assisted therapy (PAT) research. Researchers have argued that systemic issues resulting in harms to communities of color like the War on Drugs and recurrent exposure to discrimination in healthcare settings may reduce their willingness to engage in PAT research. However, there are no empirical data regarding People of Color's trust or willingness in using psychedelics with support of trained healthcare providers. Therefore, we analyzed data from a large-scale survey of people using psychedelics to explore interactions between People of Color and healthcare providers in North America. The sample included 3,547 White people, 448 People of Color, and 377 Multiracial people. A lower proportion of People of Color consumed psychedelics with the support of a trained provider but an equal proportion had disclosed psychedelic use to primary care providers. Further, People of Color were equally motivated to use psychedelics with a trained healthcare provider, used psychedelics to treat similar issues, and similarly reported psychedelics as effective with other groups. Our findings suggest that lack of trust may not fully explain the underrepresentation of People of Color in PAT research, and future studies should investigate other barriers to People of Color's inclusion in PAT research.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Damian Swieczkowski, Aleksander Kwaśny, Krzysztof Sadko, Wiesław Jerzy Cubała
{"title":"Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials.","authors":"Damian Swieczkowski, Aleksander Kwaśny, Krzysztof Sadko, Wiesław Jerzy Cubała","doi":"10.1080/02791072.2025.2491385","DOIUrl":"https://doi.org/10.1080/02791072.2025.2491385","url":null,"abstract":"<p><p>Ibogaine, a non-classical psychedelic, has gained increasing attention as a potential treatment for substance use disorders (SUD); however, a lack of commercial interest and safety-related concerns limit its clinical development. This cross-sectional study investigates the current landscape of clinical trials involving ibogaine, a non-classical psychedelic, focusing on its safety and efficacy. We extracted data from ClinicalTrials.Gov, EU Clinical Trials (https://euclinicaltrials.eu/), the EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/), and the International Clinical Trials Registry Platform (World Health Organization). After rigorous screening and deduplication, we analyzed nine trials. Our findings revealed considerable variability in methodologies, including fixed-dose and ascending-dose designs, diverse inclusion and exclusion criteria, and differing primary and secondary outcomes. Early-phase trials dominate, primarily focusing on pharmacokinetics, withdrawal symptom reduction, and safety monitoring. Key findings indicate significant differences in how safety concerns are addressed, particularly regarding ibogaine's cardiovascular risk. While preliminary evidence suggests potential therapeutic benefits, the absence of large-scale, late-phase trials limits definitive conclusions. Our study underscores the need for a standardized clinical framework to ensure reliable assessments of ibogaine's efficacy and safety. Lessons from research on classical psychedelics, and MDMA could help improve trial design and reduce issues related to blinding and expectancy bias.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brant Maclean, Amy Wilson, Andrew Allen, Vikki Schaffer, Lee Kannis-Dymand
{"title":"Ayahuasca Retreats: The Role of Awe and Mystical Experiences in Well-Being.","authors":"Brant Maclean, Amy Wilson, Andrew Allen, Vikki Schaffer, Lee Kannis-Dymand","doi":"10.1080/02791072.2025.2491378","DOIUrl":"https://doi.org/10.1080/02791072.2025.2491378","url":null,"abstract":"<p><p>Research on the positive psychological effects of psychedelics has surged since the early 2000s, particularly regarding increased well-being. Studies have demonstrated how psychedelic-occasioned mystical experiences play a key role in their positive effects, which has prompted an interest in the emotion of awe in the psychedelic context due to its similar phenomenology and associated benefits. This study examined 60 individuals following their visitation to at least one ayahuasca retreat in a country where ayahuasca use was legal or retreats are approved to use ayahuasca, hypothesizing that not only high levels of awe but mystical experiences characterized by high levels of awe would be significantly associated with higher well-being. Neither hypothesis was supported: higher levels of mystical experience with lower perceived vastness, a facet of awe, was significantly associated with higher well-being, possibly highlighting the synergistic relationship between mystical experiences and perceived vastness on well-being. The study has implications for future research, particularly in terms of understanding how the perceived vastness of a person's psychedelic experience may be modulated to mitigate distress and foster well-being.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Qualitative Inquiry into the Challenges in Overcoming Heroin Addiction Among Chinese Individuals Who Experience Voluntary Rehabilitation.","authors":"Liu Liu, Zhenni Tang, Xuemeng Li, Wing Hong Chui","doi":"10.1080/02791072.2024.2315316","DOIUrl":"10.1080/02791072.2024.2315316","url":null,"abstract":"<p><p>This study explores the intentions and experiences of individuals seeking abstinence from heroin use through voluntary rehabilitation, as well as challenges to achieving a positive outcome. This study used semi-structured interviews with 37 individuals (22 female) who used heroin and utilized rational choice theory to guide data analysis. This study found that participants tried both medical and non-medical treatment methods but faced structural and personal barriers that hindered their efforts. While ceasing heroin use would presumably benefit their health and family relationships, individuals perceived the physical, psychological, and social costs of abstinence as outweighing the potential benefits and ultimately resumed heroin use. More targeted voluntary rehabilitation programs addressing specific structural and personal barriers are therefore recommended to benefit Chinese people seeking abstinence from drug use.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"163-170"},"PeriodicalIF":2.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139723080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Baldur Jón Gústafsson, Cheneal Puljević, Emma L Davies, Monica J Barratt, Jason Ferris, Adam Winstock, Timothy Piatkowski
{"title":"Sweating for Sobriety: Exploring the Relationship Between Exercise Engagement and Substance Use Disorders.","authors":"Baldur Jón Gústafsson, Cheneal Puljević, Emma L Davies, Monica J Barratt, Jason Ferris, Adam Winstock, Timothy Piatkowski","doi":"10.1080/02791072.2024.2311143","DOIUrl":"10.1080/02791072.2024.2311143","url":null,"abstract":"<p><p>Despite various interventions available for substance use disorders, relapse rates remain substantial and, therefore, alternative strategies for attenuating dependence are needed. This study examined the associations between exercise frequency, illicit substance use, and dependence severity among a large sample of people who use drugs. The study utilized data from the Global Drug Survey 2018 (<i>N</i> = 57,110) to investigate the relationship between exercise frequency, illicit substance use, and substance dependence severity. Binomial regressions were employed to examine the relationship between exercise and SDS scores for 9 drugs. Greater exercise frequency correlated with reduced severity of substance dependence for specific drugs: cannabis (χ2 = 14.75, <i>p</i> < .001), MDMA (χ2 = 4.73, <i>p</i> = .029), cocaine (χ2 = 8.37, <i>p</i> = .015), amphetamine powder (χ2 = 6.39, <i>p</i> = .041), and methamphetamine (χ2 = 15.17, <i>p</i> < .001). These findings suggest a potential link between exercise and reduced substance use dependency. Further research is needed to understand the complex dynamics between exercise and substance use, considering potential bidirectional relationships and concurrent factors.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"223-233"},"PeriodicalIF":2.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}